Have a feature idea you'd love to see implemented?
Let us know!
INMB Inmune Bio Inc
Price (delayed)
$4.76
Market cap
$105.54M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$2.18
Enterprise value
$74.9M
INmune Bio, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The
Highlights
The debt has dropped by 77% year-on-year and by 46% since the previous quarter
INMB's quick ratio is up by 18% QoQ but it is down by 16% YoY
INMB's equity is down by 12% year-on-year but it is up by 7% since the previous quarter
The revenue has dropped by 81% year-on-year and by 51% since the previous quarter
The gross profit has shrunk by 81% YoY and by 51% QoQ
Key stats
What are the main financial stats of INMB
Market
Valuations
Earnings
Shares outstanding
22.17M
Market cap
$105.54M
Enterprise value
$74.9M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.43
Price to sales (P/S)
2,287.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,783.38
Revenue
$42,000
EBIT
-$41.27M
EBITDA
-$41.27M
Free cash flow
-$25.75M
Per share
Balance sheet
Liquidity
EPS
-$2.18
Free cash flow per share
-$1.28
Book value per share
$1.96
Revenue per share
$0
TBVPS
$1.8
Total assets
$52.78M
Total liabilities
$14.11M
Debt
$2.91M
Equity
$38.68M
Working capital
$22.03M
Debt to equity
0.08
Current ratio
2.59
Quick ratio
2.43
Net debt/EBITDA
0.74
Margins
Efficiency
Dividend
EBITDA margin
-98,266.7%
Gross margin
100%
Net margin
-98,266.7%
Operating margin
-99,557.1%
Return on assets
-79%
Return on equity
-117.5%
Return on invested capital
N/A
Return on capital employed
-105.9%
Return on sales
-98,266.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
INMB stock price
How has the Inmune Bio stock price performed over time
Intraday
4.39%
1 week
-12.5%
1 month
-8.11%
1 year
-39.82%
YTD
-57.73%
QTD
-11.69%
Financial performance
How have Inmune Bio's revenue and profit performed over time
Revenue
$42,000
Gross profit
$42,000
Operating income
-$41.81M
Net income
-$41.27M
Gross margin
100%
Net margin
-98,266.7%
The operating margin has shrunk by 122% QoQ
The net margin has dropped by 121% since the previous quarter
The revenue has dropped by 81% year-on-year and by 51% since the previous quarter
The gross profit has shrunk by 81% YoY and by 51% QoQ
Growth
What is Inmune Bio's growth rate over time
Valuation
What is Inmune Bio stock price valuation
P/E
N/A
P/B
2.43
P/S
2,287.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,783.38
The EPS has declined by 43% year-on-year and by 6% since the previous quarter
The P/B is 52% lower than the last 4 quarters average of 5.1 and 29% lower than the 5-year quarterly average of 3.4
INMB's equity is down by 12% year-on-year but it is up by 7% since the previous quarter
The revenue has dropped by 81% year-on-year and by 51% since the previous quarter
The price to sales (P/S) is 48% lower than the 5-year quarterly average of 4420.1 but 22% higher than the last 4 quarters average of 1879.3
Efficiency
How efficient is Inmune Bio business performance
Inmune Bio's ROE has plunged by 125% YoY and by 13% from the previous quarter
The ROS has dropped by 121% since the previous quarter
INMB's ROA has shrunk by 107% YoY and by 15% QoQ
Dividends
What is INMB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for INMB.
Financial health
How did Inmune Bio financials performed over time
The total liabilities fell by 21% YoY and by 8% QoQ
The current ratio has declined by 19% year-on-year but it is up by 10% since the previous quarter
The debt is 92% smaller than the equity
The debt has dropped by 77% year-on-year and by 46% since the previous quarter
The debt to equity has dropped by 72% year-on-year and by 47% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.